Good morning, you're tuned into Markets Desk, and here's what's moving the tape.
Ukrainian drones struck an oil terminal in Saint Petersburg over the weekend, part of an almost daily campaign targeting Russian energy infrastructure. The sustained bombardment has triggered a domestic fuel crisis inside Russia, piling political pressure on the Kremlin as the war grinds into its fifth year. Putin has publicly dismissed the attacks as not critical, though that framing is getting harder to sustain.
Shifting to equities, Tesla is drawing renewed attention from analysts who argue the company already trades less like an automaker and more like an artificial intelligence play. With its autonomous driving ambitions and robotics pipeline, the bull case heading into the second half of two thousand twenty six centers on AI-driven revenue streams rather than vehicle deliveries alone.
And in healthcare, investors are weighing two very different growth stories. Heartflow is leveraging AI-enabled software to carve out a dominant position in non-invasive coronary diagnostics, with a stable base of more than one thousand four hundred fifty accounts providing recurring revenue. Against that, Iovance Biotherapeutics represents a higher-risk, higher-reward cell therapy bet, making the comparison a clean study in contrasting risk profiles within the sector.
That's the tape. Markets Desk, signing off the floor.
